Nona Biosciences and AstraZeneca Partner for Cancer Therapy Breakthrough

Nona Biosciences, a prominent biotechnology company, has recently entered into a licensing agreement with AstraZeneca to develop preclinical monoclonal antibodies for targeted oncology therapies. This collaboration involves an initial payment of US$19 million to Nona Biosciences, with the potential for additional milestone payments of up to US$585 million, along with royalty payments on future sales.

The Chairman of Nona Biosciences expressed enthusiasm about the partnership with AstraZeneca, underscoring the promise of their innovative antibodies in creating new cancer treatments. AstraZeneca's Senior Vice President also highlighted the opportunity to utilize Nona's cutting-edge biologics discovery engine to progress tumor-targeted therapies.

Nona Biosciences, a subsidiary of HBM Holdings Limited, is committed to pioneering technology advancements in biotechnology. Their services encompass target validation, antibody discovery, and preclinical research, leveraging advanced antibody screening platforms and the Harbour Mice® technology to produce fully human monoclonal antibodies.

By combining leading technologies with a proficient team, Nona Biosciences aims to propel global progress in next-generation drug development. For further details, please visit their website and connect with them on LinkedIn.

The partnership between Nona Biosciences and AstraZeneca signifies a significant step forward in the quest for innovative cancer therapies. With a focus on cutting-edge research and collaboration, these companies are poised to make substantial contributions to the field of oncology, offering hope for improved treatments and outcomes for patients worldwide.